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Objective: To evaluate the prevalence of known risk factors for contrast-induced nephropathy (CIN) and their association 
with the actual occurrence of CIN in patients undergoing intravenous contrast-enhanced computed tomography (CECT) in 
Korea.
Materials and Methods: Patients who underwent CECT in 2008 were identified in the electronic medical records of 16 
tertiary hospitals of Korea. Data on demographics, comorbidities, prescriptions and laboratory test results of patients were 
collected following a standard data extraction protocol. The baseline renal function was assessed using the estimated 
glomerular filtration rate (eGFR). We identified the prevalence of risk factors along the eGFR strata and evaluated their 
influence on the incidence of CIN, defined as a 0.5 mg/dL or 25% increase in serum creatinine after CECT.
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INTRODUCTION
An intravenous administration of iodinated contrast media 
during contrast-enhanced computed tomography (CECT) 
can lead to contrast-induced nephropathy (CIN) (1), which 
is known to increase the length of hospital stay, costs of 
medical care and the risk of permanent renal impairment (2, 
3). Although serious clinical outcomes after CIN have been 
reported to be rare (4-7), efforts to reduce CIN caused by 
CECT are worthwhile (5, 6).
Current guidelines for CIN recommend a pre-contrast 
assessment of patients to identify risk factors such 
as impaired renal function, diabetes mellitus (DM) 
and congestive heart failure (CHF) in order to prompt 
appropriate actions including measurement of the serum 
creatinine (SCr) and adequate hydration for high risk 
patients (4, 8). However, a gap between the evidence-
based guidelines and the daily practice of radiologists for 
CIN prevention in CECT patients has been identified (9), 
which is likely due to the logistics needed to enable SCr 
measurement, intravenous hydration and serial follow-up of 
SCr in the setting of a radiology department (10). The first 
step should be to measure the size of the population who 
are at risk of CIN, which would depend on the prevalence 
of the major risk factors to develop a feasible protocol for 
the prevention of CIN by CECT. Accordingly, the prevalence 
data on risk factors of CIN in patients undergoing CECT 
are essential for designing a control strategy of CIN. Thus 
far, such data have been collected mostly at a single 
institution. For this reason, we conducted a multi-center 
observational study to evaluate the prevalence of known 
risk factors for CIN and their association with the actual 
incidence of CIN in patients undergoing CECT in Korea.
MATERIALS AND METHODS
Data Collection
The study was compliant with the Personal Information 
Protection Act of the Republic of Korea. The study protocol 
was reviewed and approved by the Institutional Review 
Boards of each participating hospital with a waiver for 
informed consents of study participants.
Radiology departments of 16 tertiary hospitals in Korea 
participated in this study. We developed a method to 
extract data on CECT, pre-CT medication use, comorbidities 
and laboratory tests from the electronic medical records 
(EMRs) or computerized provider order entry (CPOE) systems 
of participating hospitals in a standardized format, using 
the codes originally to be used in the Korean National 
Health Insurance (KNHI) for a reimbursement claim. KNHI 
has been covering the entire Korean population since 
1999. Out of the 16 participating centers in this study, 13 
hospitals were using EMR in 2008, which reflects a higher 
adoption rate of EMR systems than those of other countries 
(11). Although not all hospitals were using comprehensive 
EMR systems, all participating centers were using electronic 
communication systems for medications, laboratory tests, 
diagnostic codes and CECTs. Physicians usually entered the 
diagnosis and prescription into the system by themselves 
during that period of time.
We retrospectively identified all patients undergoing 
CECT with intravenous iodinated contrast media in 2008 by 
accessing the EMRs or CPOEs of the participating hospitals. 
The collected variables included the age (with ages 70 years 
or older being categorized as advanced age) and sex of the 
patients, SCr level and diagnostic information on DM, CHF, 
gout and hypertension (HT). We also extracted prescription 
information of the patients to determine whether they took 
potential nephrotoxic medications including non-steroid 
anti-inflammatory drugs (NSAIDs), diuretics, angiotensin 
converting enzyme inhibitors (ACEIs), and angiotensin 
Results: Of 432425 CECT examinations in 272136 patients, 140838 examinations in 101487 patients met the eligibility 
criteria for analysis. The mean age of the participants was 57.9 ± 15.5 years; 25.1% of the patients were older than 70 
years. The prevalence of diabetes mellitus was 11.9%, of hypertension 13.7%, of gout 0.55% and of heart failure was 1.7%. 
Preventive measures were used in 40238 CECT examinations (28.6%). The prevalence of risk factors and use of preventive 
measures increased as the renal function became worse. A CIN was occurred after 3103 (2.2%) CECT examinations, revealing 
a significant association with decreased eGFR, diabetes mellitus, and congestive heart failure after adjustment.
Conclusion: Risk factors for CIN are prevalent among the patients undergoing CECT. Preventive measures were seemingly 
underutilized and a system is needed to improve preventive care.
Index terms: Contrast-induced nephropathy; Contrast-enhanced computed tomography; Prevalence; Risk factor
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receptor blockers (ARBs) on the day of CECT and whether 
they received normal saline (NS) ≥ 500 mL, N-acetylcysteine 
(NAC) and sodium bicarbonate within 1 day prior to CECT as 
protective measures for CIN. 
The extracted data were transmitted to the coordinating 
center for further data management and analysis after 
encryption according to the Electronic Communication 
Fundamental Law of Korea. Of 432425 CECT examinations 
performed in 272136 patients at the 16 participating 
hospitals in 2008, patients who were older than 15 years, 
who had at least 1 SCr test within 14 days before CECT and 
1 SCr test within 3 days after CECT and whose pre-CECT 
estimated glomerular filtration rate (eGFR) (see below) was 
equal to or higher than 15 mL/min/1.73 m2 were selected 
for analysis. A total of 140838 CECT examinations performed 
in 101487 patients were included for analysis (Fig. 1). 
As the eGFR can identify more patients with renal 
insufficiency than SCr (12), we calculated the eGFR of 
the pre-CECT state in each patient with the 4-variable 
Modification of Diet in Renal Diseases formula (13): 
eGFR (mL/min/1.73 m2) = 186 x (SCr)-1.154 x (age)-0.203 x 
(0.742 if female) x (1.212 if black)
We found that 2 hospitals had used the isotope dilution 
mass spectrometry traceable SCr assay during the study 
period; we thus used the following formula for the 2 
hospitals considering the utilization of standardized SCr 
assay: 
eGFR (mL/min/1.73 m2) = 175 x (standardized SCr)-1.154 x 
(age)-0.203 x (0.742 if female) x (1.212 if black)
Based on the calculated eGFR prior to the CECT, we 
categorized the baseline renal function into 4 categories: 
eGFR ≥ 60 mL/min/1.73 m2, 45–59 mL/min/1.73 m2, 30–44 
mL/min/1.73 m2, and 15–29 mL/min/1.73 m2.
Statistical Analysis
We appropriately presented the mean age ± standard 
deviation and the distribution of risk factors for CIN in 
frequency for the entire dataset and according to the eGFR 
strata with 95% confidence intervals (CIs). The rate of 
preventive measures use was described, categorized into 
either when NS (with our without combination with other 
agents) was used or when it was not used.
The eGRF was dichotomized by the value of 45 mL/
min/1.73 m2 to analyze the association of the risk factors 
with the actual incidence of CIN (4). The most recent 
SCr within the 14 days before each CECT was used as the 
baseline. The highest SCr within the 3 days after the CECT 
was used as the follow-up SCr to determine the incidence 
of CIN. We calculated the difference between the follow-
up and baseline SCr and CIN was defined as an increase 
of 0.5 mg/dL or 25% increase from the baseline (14). We 
described the characteristics of the CIN group versus the 
non-CIN group, showing the relative risk for CIN by each 
risk factor using the generalized estimating equations, 
which was the appropriate statistical model for our data 
which included patients who had undergone multiple CECT 
procedures. We also analyzed the data with the conditional 
logistic regression following the propensity score matching 
to eliminate the indication bias in estimating the 
effectiveness of preventive measures. After constructing 
a logistic regression model to calculate the probability of 
using preventive measures before CECT with the c-statistics 
of 0.79 we matched 1 non-user to each user according to 
the probability of using preventive measures such that 
the difference in the probability was less than 0.00001 
within the user/non-user pair using a greedy algorithm. In 
addition, the incidence of CIN was determined for each risk 
factor after stratification by the use of preventive measures. 
All statistical tests were 2-sided and p values < 0.05 were 
considered statistically significant. The SAS version 9.1 
(SAS Institute, Inc., Cary, NC, USA) was used for statistical 
analysis.
272136 patients with 432425 CECTs
101487 patients with 140838 CECTs
139425 patients without serum creatinine 
test prior to CECT
27102 patients without serum creatinine 
test in 3 days after CECT
2961 pediatric patients (age ≤ 15)
1161 patients with eGFR < 15
Fig. 1. Flow diagram of patient selection. CECT = contrast-
enhanced computed tomography, eGFR = estimated glomerular 
filtration rate
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RESULTS
Of 140838 CECT examinations was the baseline eGFR 
greater than or equal to 60 mL/min/1.73 m2 in 118424 
(84.1%), 45–59 mL/min/1.73 m2 in 16630 (11.8%), 30–44 
mL/min/1.73 m2 in 4421 (3.1%), and 15–29 mL/min/1.73 
m2 in 1363 (1.0%) (Table 1). The prevalence of risk factors 
showed an increasing tendency as the renal function 
worsened. However, the proportion of those in advanced 
age in the group with the worst renal function was smaller 
than that in the 3rd eGFR group. The mean age of the group 
with an eGFR of 15–29 mL/min/1.73 m2 was 67.2 (± 13.0), 
which was smaller than that of the 3rd eGFR group (p < 
0.01). The prevalence of risk factors for CIN was 25.1% (95% 
CI: 24.9–25.3) for the advanced age; 11.9% (11.7–12.1) 
for DM; 13.7% (13.5–13.8) for HT; 1.7% (1.6–1.8) for CHF; 
and 0.55% (0.51–0.59) for gout. NSAIDs were prescribed 
in 25.2% (25.0–25.4), diuretics in 11.6% (11.4–11.7) and 
ACEI/ARB were prescribed for the day of CECT in 11.8% 
(11.6–11.9) of cases. 
Preventive measures were used in 40238 CECT 
examinations (28.6%), 37448 (26.6%) of which were NS 
with or without combination with other agents (Table 2). 
There was a prominent increase in preventive measures 
Table 1. Prevalence of Risk Factors for Contrast Induced Nephropathy in Total of 140838 Contrast Enhanced Computed Tomography 
Examinations
Characteristics
eGFR ≥ 60 eGFR 45–59 eGFR 30–44 eGFR 15–29 All CECT
N % N % N % N    % N % (95% CI)
Age (mean ± SD) 56.1 ± 15.4 67.3 ± 11.4 68.5 ± 12.6 67.2 ± 13.0 57.9 ± 15.5
Advanced age (age ≥ 70) 24700 20.9 7657 46.0 2356 53.3 655 48.1 35368 25.1 (24.9–25.3)
Diabetes mellitus 12193 10.3 3090 18.6 1053 23.8 409 30.0 16745 11.9 (11.7–12.1)
Hypertension 13639 11.5 3853 23.2 1283 29.0 469 34.4 19244 13.7 (13.5–13.8)
Congestive heart failure 1349 1.1 618 3.7 315 7.1 121 8.9 2403 1.7 (1.6–1.8)
Gout 382 0.3 223 1.3 123 2.8 43 3.2 771 0.55 (0.51–0.59)
NSAIDs 28887 24.4 4893 29.4 1307 29.6 423 31.0 35510 25.2 (25.0–25.4)
Diuretics 13028 11.0 2353 14.2 661 15.0 243 17.8 16285 11.6 (11.4–11.7)
ACEI or ARB 13309 11.2 2371 14.3 663 15.0 229 16.8 16572 11.8 (11.6–11.9)
All participants 118424 84.1 16630 11.8 4421 3.1 1363 1.0 140838 100
Note.— Estimated glomerular filtration rate (eGFR) was calculated using MDRD formula whose unit was mL/min/1.73 m2. ACEI = 
angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker, CECT = contrast-enhanced computed tomography, CI = 
confidence interval, MDRD = Modification of Diet in Renal Diseases, NSAIDs = non-steroidal anti-inflammatory drugs, SD = standard 
deviation 
Table 2. Use of Preventive Measures
Preventive Measures
eGFR ≥ 60 eGFR 45–59 eGFR 30–44 eGFR 15–29 All CECT
N % N % N % N % N %
No 85514 72.2 11890 71.5 2552 57.7 644 47.3 100600 71.4
Yes 32910 27.8 4740 28.5 1869 42.3 719 52.7 40238 28.6
NS containing 30842 26.0 4371 26.3 1640 37.1 595 43.6 37448 26.6
NS 28660 24.2 3486 21.0 1017 23.0 301 22.1 33464 23.8
NS + NAC 1671 1.4 712 4.3 486 11.0 173 12.7 3042 2.2
NS + SB 441 0.4 132 0.8 88 2.0 78 5.7 739 0.5
NS + NAC + SB 70 0.1 41 0.3 49 1.1 43 3.2 203 0.1
NS non-containing 2068 1.8 369 2.2 229 5.2 124 9.1 2790 2.0
NAC 1608 1.4 325 2.0 203 4.6 95 7.0 2231 1.6
SB 435 0.4 36 0.2 11 0.3 9 0.7 491 0.3
NAC + SB 25 0.0 8 0.1 15 0.3 20 1.5 68 0.05
All participants 118424 84.1 16630 11.8 4421 3.1 1363 1.0 140838 100.0
Note.— Estimated glomerular filtration rate (eGFR) was calculated using MDRD formula whose unit was mL/min/1.73 m2. CECT = 
contrast-enhanced computed tomography, MDRD = Modification of Diet in Renal Diseases, NAC = N-acetylcysteine, NS = normal saline, SB 
= sodium bicarbonate
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as eGFR dropped below 45 mL/min/1.73 m2, which was 
mostly attributed to the increased use of other preventive 
measures than NS. 
We identified 3103 cases of CIN, which accounted for 
2.2% of all CECT examinations. All of the risk factors were 
more prevalent in the CIN group and the difference was 
statistically significant except for nephrotoxic medications 
at the univariable analysis (Table 3). In the multivariable 
analysis, however, decreased eGFR, DM, and CHF only 
remained statistically significant after the adjustment. The 
most prominent risk factor was the decreased eGFR with an 
adjusted relative risk (aRR) of 11.52 (10.43–12.73) for CIN. 
Gout was with an aRR of 0.78 (0.52–1.18) insignificant 
after the adjustment. The aRR for advanced age was 0.84 
(0.76–0.92). Preventive measures were related to CIN events 
with an aRR of 2.83 (2.62–3.07). Using the propensity of 
using preventive measures, we matched the 27369 CECT 
examinations performed after preventive measures to the 
same number of CECT examinations performed without 
preventive measures within the predefined probability 
difference of using preventive measures. However, the odds 
ratio (OR) for developing CIN was 2.70 (95% CI: 2.39–3.05) 
for the group that used preventative measures compared 
with the cases that did not use preventative measures, 
similar to the results of the multivariable analysis.
When we calculated the incidence rate ratio of CIN for 
each risk factor group stratified by the use of preventive 
measures, we uniformly found smaller incidence rate ratios 
for each significant CIN risk factor in the cases where 
preventive measures were used than in those cases were 
no preventative measures were used. The aRR for DM were 
1.19 (95% CI: 1.02–1.40), for CHF 1.73 (1.24–2.41) and 
for decreased eGFR 14.17 (12.21–16.44) in cases without 
use of preventative measures and 1.07 (0.91–1.26), 1.38 
(1.09–1.76), and 9.96 (8.79–11.29), respectively, in cases 
with use of preventive measures. For the decreased eGFR, 
the 95% CI of the risk estimates was not overlapping, which 
suggested a significant decrease in CIN risk by preventive 
measures. 
DISCUSSION
This study analyzed the prevalence of CIN risk factors and 
their relationship with the actual incidents of CIN using 
large data obtained from 16 tertiary hospitals in Korea. 
The incidence of CIN from all CECT procedures included to 
the analysis was 2.2% which was comparable to that found 
in previous studies. Balemans et al. (5) reported 23 CIN 
cases out of 944 procedures (2.43%), without the need for 
hemodialysis in any of the cases. Katzberg and Lamba (15)
reviewed studies including 1075 patients with intravenous 
contrast media showing a 5.1% incidence of CIN without 
dialysis or mortality. El-Hajjar et al. (16) presented a very 
low incidence of CIN: only 4 CINs were reported out of 400 
patients who underwent CT angiography with preventive 
measures. Although the prevalence of risk factors and the 
use of preventive measures varied among studies, the low 
incidence of CIN among CECT patients was consistent to 
previous studies. 
A decreased renal function (eGFR < 45 mL/min/1.73 
Table 3. Association of Risk Factors of CIN with Actual Occurrence of CIN
Risk Factors
Non-CIN CIN Univariable Analysis Multivariable Analysis
N = 137735 % N = 3103 % RR* (95% CI) RR* (95% CI)
Diabetes mellitus 16238 11.8 507 16.3 1.50 (1.35–1.66) 1.13 (1.01–1.27)
Hypertension 18697 13.6 547 17.6 1.37 (1.24–1.51) 0.88 (0.79–0.99)
Congestive heart failure 2249 1.6 154 5.0 3.21 (2.69–3.84) 1.49 (1.22–1.82)
Gout 744 0.5 27 0.9 1.70 (1.16–2.50) 0.78 (0.52–1.18)
Advanced age (≥ 70) 34428 25.0 940 30.3 1.36 (1.25–1.47) 0.84 (0.76–0.92)
Decreased eGFR (< 45) 4813 3.5 971 31.3 12.99 (11.92–14.17) 11.52 (10.43–12.73)
NSAIDs 34694 25.2 816 26.3 1.07 (0.98–1.16) 0.92 (0.83–1.02)
Diuretics 15917 11.6 368 11.9 1.03 (0.92–1.16) 0.93 (0.76–1.12)
ACEI or ARB 16177 11.8 395 12.7 1.10 (0.98–1.23) 1.07 (0.88–1.31)
Preventive measures 38474 27.9 1764 56.9 3.33 (3.08–3.60) 2.83 (2.62–3.07)
Note.— Estimated glomerular filtration rate (eGFR) was calculated using MDRD formula whose unit was mL/min/1.73 m2. *Estimates 
were calculated using generalized estimating equations. ACEI = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor 
blocker, CI = confidence interval, CIN = contrast-induced nephropathy, MDRD = Modification of Diet in Renal Diseases, NSAID = non-
steroidal anti-inflammatory drugs, RR = relative risk
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m2) was the most important independent risk factor for 
the development of CIN, although the aRR was larger 
than that of the previous studies. We found that DM, CHF 
and decreased renal function were associated with CIN; 
however, the age was associated with a decrease in the CIN. 
Many studies reported age as an independent risk factor of 
CIN (17-19). As we mentioned in the results section, the 
mean age of the group with an eGFR 15–29 mL/min/1.73 
m2 was 67.2 years (± 13.0), which was smaller than that 
in the eGFR 30–44 mL/min/1.73 m2 group. Although a 
strong association between age and the deterioration of 
renal function has been identified (20), the mean all-cause 
mortality rate was the highest in elderly patients with low 
eGFR (21). The age distribution across eGFR groups in our 
data reflect the low chance of survival of elderly patients 
with advanced stage of chronic kidney disease. Furthermore, 
it was obvious that all the other risk factors increased as 
the patients became older. For those reasons, the incidence 
of CIN could be explained by the effect of risk factors other 
than advanced age in a multivariable model.
The adjusted OR was 2.83 (2.62–3.07) for preventive 
measures. However, it is well known that those treatments 
have been beneficial in prevention against CIN in patients 
who underwent a CECT. Like many other observational studies, 
our study was susceptible to unmeasured confounding. 
Regarding the results of the multivariable model, we did not 
attempt to conclude that preventive measures may increase 
the risk of CIN. This counterintuitive adjusted OR might 
have resulted from the fact that the preventive measures 
were likely performed in patients with a higher risk of CIN 
while some of the risk factors could not be accounted our 
statistical adjustment. The relevant data available in the 
medical records of the patients were likely not comprehensive 
enough to nullify the effect of all the confounders. Similarly, 
the results from the propensity score matching analysis 
also suggested that the input variables used to calculate 
the propensity score were not sufficient enough to properly 
evaluate the effect of the preventive measures.
Our data clearly showed that the risk factors of CIN were 
more prevalent in patients with a lower eGFR (Table 1) and 
that preventive measures became more prevalent as the 
eGFR decreased (Table 2). Therefore, it was obvious that 
patients with risk factors of CIN were more likely to have 
preventive measures referring to this data. We found this 
tendency consistently in every stratum of CIN risk factors 
and in the patient subgroup without any risk factors prior 
to CECT. Weisbord et al. (7) also reported a similar tendency 
that patients who were hospitalized or had lower baseline 
eGFR levels were more likely to undergo preventive measures 
and were seemingly more likely to derive benefit from such 
care. The hydration (OR 1.6, 95% CI: 0.6–4.1) and NAC (OR 
2.4, 95% CI: 1.9–5.8) were associated with CIN when they 
defined CIN as a 25% increase in SCr.
Our results should be interpreted with caution due to 
several limitations. Although we pooled the electronic data 
of a very large population, this was not a random sample 
of the target population; thus we cannot say that it is 
generalizable to all CECT patients. Carstensen et al. (22) 
reported a prevalence of renal insufficiency that was very 
similar to this study. However, the study participants could 
have had more risk factors than ordinary CECT patients, as 
we selected patients from tertiary hospitals, which might 
still result in an over-estimation of the prevalence of risk 
factors. A large number of patients without SCr checked 
either before or after CECT were excluded, which could have 
biased the estimates. We found that the patients excluded 
from the analysis due to the lack of SCr measurements had 
significantly low rates of risk factors than those who were 
analyzed in the study (Appendix). Therefore, the excluded 
patients may have been less likely to develop CIN than the 
study participants. Although we could not directly assess 
the incidence of CIN in the patients who were excluded 
due to the lack of SCr measurements, the prevalence of 
risk factors and incidence of CIN might have been over-
estimated in our study. Another important aspect of the 
study population was derived from the fact that we did not 
exclude patients who were on dialysis, but we excluded 
patients with an eGFR below 15. Considering that there 
might have been some patients who were on dialysis with 
an eGFR of at least 15, this study might have included a 
small number of dialysis patients. However, it is likely that 
most of the patients on peritoneal dialysis were excluded, 
so that only a small proportion of patients on hemodialysis 
were misclassified into the group of study participants.
The incidence of CIN was not directly compared to the 
population undergoing non-contrast studies, even though 
a control group would be essential to elucidate the causal 
relationship between CECT and CIN. In terms of incidence, 
the interval for SCr measurements was irregular as the data 
were collected retrospectively, which could have caused 
a detection bias to underestimate the CIN incidence. The 
timing and rate of hydration were not available; thus our 
operational definition of the use of NS as a preventive 
measure might have inflated the usage rate of the 
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preventive measures.
Some studies have reported the setting of care as an 
independent risk factor (7) and have noted a higher 
incidence of CIN in inpatients. We could not identify any 
difference in the incidence between the inpatients and 
outpatients since we did not collect information on the 
setting of care. For the nephrotoxic medications, the 
medication use a few days before CECT could have had a 
similar toxic effect that caused an increase in SCr though 
we defined the exposure as the prescription for the day of 
CECT. On the other hand, the physician might have given 
instructions to skip the medication to the patient on the 
day of CECT, some of which might have not been precisely 
noted in the medical records. Finally, the use of any other 
not prescribed nephrotoxic medication such as herbal 
medicine, if existed, could not be included in our analysis.
In conclusion, we found that DM, CHF and a decreased 
eGFR were significantly associated with the occurrence 
of CIN after CECT in Korea and preventive measures were 
underutilized. Further efforts are needed to develop a 
system for the identification of susceptible patients and for 
the facilitation of preventive measures are needed.
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Advanced Age
P
Yes, n (%) No, n (%)
Patients excluded due to lack of pre-CT SCr (n = 139425)   22438 (16.1)   116987 (83.9) < 0.001
Patients excluded due to lack of post-CT SCr (n = 27102) 6055 (22.3) 21047 (77.7) < 0.001
Study participants (n = 101487)   26323 (25.9) 75164 (74.1)
–APPENDIX–
Prevalence of Risk Factors for CIN in Patients Who Were Excluded Due to Lack of SCr
Diabetes Mellitus
P
Yes, n (%) No, n (%)
Patients excluded due to lack of pre-CT SCr (n = 139425) 10874 (7.8)   128551 (92.2) < 0.001
Patients excluded due to lack of post-CT SCr (n = 27102) 2979 (11.0) 24123 (89.0) 0.002
Study participants (n = 101487)   11828 (11.7) 89659 (88.3)
Congestive Heart Failure
P
Yes, n (%) No, n (%)
Patients excluded due to lack of pre-CT SCr (n = 139425) 840 (0.6)  138585 (99.4) < 0.001
Patients excluded due to lack of post-CT SCr (n = 27102) 475 (1.8) 26627 (98.2)  0.001
Study participants (n = 101487)  2090 (2.1) 99397 (97.9)
Gout
P
Yes, n (%) No, n (%)
Patients excluded due to the lack of pre-CT SCr (n = 139425)   409 (0.3) 139016 (99.7) < 0.001
Patients excluded due to the lack of post-CT SCr (n = 27102)   125 (0.5) 26977 (99.5)  0.008
Study participants (n = 101487)   606 (0.6) 100881 (99.4)
